Nadia Terranova
Overview
Explore the profile of Nadia Terranova including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
211
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Villette C, Dupuy N, Brightman F, Zimmermann A, Lignet F, Zenke F, et al.
Br J Cancer
. 2025 Jan;
132(5):481-491.
PMID: 39875558
Background: Promising cancer treatments, such as DDR inhibitors, are often challenged by the heterogeneity of responses in clinical trials. The present work aimed to build a computational framework to address...
2.
Lu H, Klopp-Schulze L, Mukker J, Li D, Kuroki Y, Bolleddula J, et al.
Clin Transl Sci
. 2024 Oct;
17(10):e70050.
PMID: 39445632
With the International Conference on Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) E17 guidelines in effect from 2018, the design of Asia-inclusive multiregional clinical trials (MRCTs) has...
3.
Amato F, Strotmann R, Castello R, Bruns R, Ghori V, Johne A, et al.
Clin Transl Sci
. 2024 Sep;
17(9):e70010.
PMID: 39222377
Tepotinib is approved for the treatment of patients with non-small-cell lung cancer harboring MET exon 14 skipping alterations. While edema is the most prevalent adverse event (AE) and a known...
4.
Generative models for synthetic data generation: application to pharmacokinetic/pharmacodynamic data
Jiang Y, Garcia-Duran A, Losada I, Girard P, Terranova N
J Pharmacokinet Pharmacodyn
. 2024 Aug;
51(6):877-885.
PMID: 39192091
The generation of synthetic patient data that reflect the statistical properties of real data plays a fundamental role in today's world because of its potential to (i) be enable proprietary...
5.
Losada I, Terranova N
CPT Pharmacometrics Syst Pharmacol
. 2024 Jul;
13(8):1289-1296.
PMID: 38992975
The advent of machine learning has led to innovative approaches in dealing with clinical data. Among these, Neural Ordinary Differential Equations (Neural ODEs), hybrid models merging mechanistic with deep learning...
6.
Terranova N, Venkatakrishnan K
Clin Pharmacol Ther
. 2023 Dec;
115(4):720-726.
PMID: 38105646
The increasing breadth and depth of resolution in biological and clinical data, including -omics and real-world data, requires advanced analytical techniques like artificial intelligence (AI) and machine learning (ML) to...
7.
Naik K, Goyal R, Foschini L, Chak C, Thielscher C, Zhu H, et al.
Clin Pharmacol Ther
. 2023 Dec;
115(4):673-686.
PMID: 38103204
Technological innovations, such as artificial intelligence (AI) and machine learning (ML), have the potential to expedite the goal of precision medicine, especially when combined with increased capacity for voluminous data...
8.
Milenkovic-Grisic A, Terranova N, Mould D, Vugmeyster Y, Mrowiec T, Machl A, et al.
CPT Pharmacometrics Syst Pharmacol
. 2023 Dec;
13(1):143-153.
PMID: 38087967
This analysis aimed to quantify tumor dynamics in patients receiving either bintrafusp alfa (BA) or pembrolizumab, by population pharmacokinetic (PK)-pharmacodynamic modeling, and investigate clinical and molecular covariates describing the variability...
9.
Terranova N, Renard D, Shahin M, Menon S, Cao Y, Hop C, et al.
Clin Pharmacol Ther
. 2023 Sep;
115(4):658-672.
PMID: 37716910
Recent breakthroughs in artificial intelligence (AI) and machine learning (ML) have ushered in a new era of possibilities across various scientific domains. One area where these advancements hold significant promise...
10.
Courlet P, Abler D, Guidi M, Girard P, Amato F, Violi N, et al.
CPT Pharmacometrics Syst Pharmacol
. 2023 Jun;
12(8):1170-1181.
PMID: 37328961
The development of immune checkpoint inhibitors (ICIs) has revolutionized cancer therapy but only a fraction of patients benefits from this therapy. Model-informed drug development can be used to assess prognostic...